Aflibercept Patent Litigation
The scientific causation theory is based on the mechanism of VEGF inhibition by Aflibercept, which can induce immune responses and inflammation. Scientific literature and expert testimony support that immune complex formation and immune activation pathways plausibly lead to intraocular inflammation and vision impairment, especially in susceptible individuals.
3
Pending actions
10
Total actions filed
Active
Status
04/11/2024
Established
Filing deadline
Filing deadlines are governed by federal patent law statutes of limitations, typically six years for patent infringement claims, with procedural deadlines set by court orders following case management conferences, transfer orders, and scheduling orders.
Who qualifies
Plaintiffs must demonstrate documented exposure to Aflibercept (Eylea or biosimilars) and a diagnosis of related ophthalmic conditions such as AMD or diabetic macular edema. Specific dosage thresholds, exposure durations, or diagnostic codes are not explicitly detailed in publicly available court documents but are generally inferred from medical records and treatment histories.
Products involved
- Eylea
- Pavblu
- Yesafili
- Opuviz
Alleged injuries
- intraocular inflammation
- vision loss
- immune responses
Bellwether trials
The trial schedule for MDL-3103 has included initial dates in April 2024, with ongoing procedural activity through late 2025. Specific bellwether trial dates are not publicly disclosed, but procedural schedules and recent filings suggest active litigation with scheduled motions and discovery deadlines. Recent settlements with biosimilar manufacturers (e.g., Biocon, Sandoz, Formycon) indicate resolution of some disputes, but no specific recent verdicts are publicly reported.
Settlement landscape
Recent settlements in biosimilar disputes involving Regeneron and biosimilar manufacturers such as Samsung Bioepis, Sandoz, and Formycon suggest case values can reach into tens of millions of dollars, with some cases settling before trial. Confidentiality of specific amounts limits precise quantification.
Lead counsel
- Brett Milbourn, Joe Kronawitter (Horn Aylward & Bandy, LLC)
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
